Cargando…

The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review

The Omicron variant of SARS-CoV-2 was detected in October 2021 and exhibited high transmissibility, immune evasion, and reduced severity when compared to the earlier variants. The lesser vaccine effectiveness against Omicron and its reduced severity created vaccination hesitancy among the public. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarkar, Aparajita, Omar, Sara, Alshareef, Aya, Fanous, Kareem, Sarker, Shaunak, Alroobi, Hasan, Zamir, Fahad, Yousef, Mahmoud, Zakaria, Dalia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234134/
https://www.ncbi.nlm.nih.gov/pubmed/37254497
http://dx.doi.org/10.1080/21645515.2023.2212568
_version_ 1785052415951634432
author Sarkar, Aparajita
Omar, Sara
Alshareef, Aya
Fanous, Kareem
Sarker, Shaunak
Alroobi, Hasan
Zamir, Fahad
Yousef, Mahmoud
Zakaria, Dalia
author_facet Sarkar, Aparajita
Omar, Sara
Alshareef, Aya
Fanous, Kareem
Sarker, Shaunak
Alroobi, Hasan
Zamir, Fahad
Yousef, Mahmoud
Zakaria, Dalia
author_sort Sarkar, Aparajita
collection PubMed
description The Omicron variant of SARS-CoV-2 was detected in October 2021 and exhibited high transmissibility, immune evasion, and reduced severity when compared to the earlier variants. The lesser vaccine effectiveness against Omicron and its reduced severity created vaccination hesitancy among the public. This review compiled data reporting the relative prevalence of Omicron as compared to the early variants to give an insight into the existing variants, which may shape the decisions regarding the targets of the newly developed vaccines. Complied data revealed more than 90% prevalence within the infected cohorts in some countries. The BA.1 subvariant predominated over the BA.2 during the early stages of the Omicron wave. Moreover, BA.4/BA.5 subvariants were detected in South Africa, USA and Italy between October 2021 and April 2022. It is therefore important to develop vaccines that protect against Omicron as well as the early variants, which are known to cause more severe complications.
format Online
Article
Text
id pubmed-10234134
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-102341342023-06-02 The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review Sarkar, Aparajita Omar, Sara Alshareef, Aya Fanous, Kareem Sarker, Shaunak Alroobi, Hasan Zamir, Fahad Yousef, Mahmoud Zakaria, Dalia Hum Vaccin Immunother Coronavirus The Omicron variant of SARS-CoV-2 was detected in October 2021 and exhibited high transmissibility, immune evasion, and reduced severity when compared to the earlier variants. The lesser vaccine effectiveness against Omicron and its reduced severity created vaccination hesitancy among the public. This review compiled data reporting the relative prevalence of Omicron as compared to the early variants to give an insight into the existing variants, which may shape the decisions regarding the targets of the newly developed vaccines. Complied data revealed more than 90% prevalence within the infected cohorts in some countries. The BA.1 subvariant predominated over the BA.2 during the early stages of the Omicron wave. Moreover, BA.4/BA.5 subvariants were detected in South Africa, USA and Italy between October 2021 and April 2022. It is therefore important to develop vaccines that protect against Omicron as well as the early variants, which are known to cause more severe complications. Taylor & Francis 2023-05-30 /pmc/articles/PMC10234134/ /pubmed/37254497 http://dx.doi.org/10.1080/21645515.2023.2212568 Text en © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
spellingShingle Coronavirus
Sarkar, Aparajita
Omar, Sara
Alshareef, Aya
Fanous, Kareem
Sarker, Shaunak
Alroobi, Hasan
Zamir, Fahad
Yousef, Mahmoud
Zakaria, Dalia
The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review
title The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review
title_full The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review
title_fullStr The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review
title_full_unstemmed The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review
title_short The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review
title_sort relative prevalence of the omicron variant within sars-cov-2 infected cohorts in different countries: a systematic review
topic Coronavirus
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234134/
https://www.ncbi.nlm.nih.gov/pubmed/37254497
http://dx.doi.org/10.1080/21645515.2023.2212568
work_keys_str_mv AT sarkaraparajita therelativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview
AT omarsara therelativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview
AT alshareefaya therelativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview
AT fanouskareem therelativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview
AT sarkershaunak therelativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview
AT alroobihasan therelativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview
AT zamirfahad therelativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview
AT yousefmahmoud therelativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview
AT zakariadalia therelativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview
AT sarkaraparajita relativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview
AT omarsara relativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview
AT alshareefaya relativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview
AT fanouskareem relativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview
AT sarkershaunak relativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview
AT alroobihasan relativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview
AT zamirfahad relativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview
AT yousefmahmoud relativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview
AT zakariadalia relativeprevalenceoftheomicronvariantwithinsarscov2infectedcohortsindifferentcountriesasystematicreview